Brief: Brazilian Health Regulatory Agency (Anvisa) Authorizes Sorrento Phase 2 Trial Of Covi-Msc In Long-Hauler Covid-19 Patients

Sorrento Therapeutics

18/01/2022 14:30

Jan 18 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * BRAZILIAN HEALTH REGULATORY AGENCY (ANVISA) AUTHORIZES
SORRENTO
PHASE 2 CLINICAL TRIAL OF COVI-MSC IN COVID-19 PATIENTS WITH
PERSISTENT PULMONARY COMPROMISE AFTER RECOVERY (LONG-HAULER)
    * SORRENTO THERAPEUTICS INC - BRAZIL PHASE 2 PULMONARY
LONG-HAULER
CLINICAL TRIAL OF COVI-MSC IS NOW AUTHORIZED TO PROCEED

Source text for Eikon:  ID:nGNX8Qmm7N 
Further company coverage:  SRNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))